Related Experiment Video
Updated: Jan 26, 2026

Handling Techniques to Reduce Stress in Mice
Published on: September 25, 2021
Delta-opioid receptor antagonist naltrindole reduces oxycodone addiction and constipation in mice
Pao-Pao Yang1, Teng-Kuang Yeh2, Horace H Loh3
1Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Miaoli County, 35053, Taiwan, ROC; Department of Pharmacology, National Defense Medical Center, Taipei City, 11490, Taiwan, ROC.
Abstract:
Oxycodone, a widely prescribed and very potent oral opioid analgesic agent, is highly addictive and has many side effects, including troublesome constipation. Our studies in mice indicated that pretreatment of naltrindole did not significantly affect the analgesic efficacy of oxycodone but attenuated the tolerance and withdrawal induced by chronic oxycodone administration. Naltrindole also attenuated the oxycodone-induced rewarding and re-instatement behaviors, as shown by the conditioned place preference test. Further, oxycodone-induced decrease in intestinal transit (i.e., constipation) was reduced by naltrindole. However, naltrindole did not block the respiratory depression produced by oxycodone. Taken together, these data suggest that naltrindole can attenuate some major side effects while retaining the analgesic efficacy of oxycodone in mice. Naltrindole and oxycodone may have the potential to be a potent analgesic combination with much lower levels of oxycodone's side effects of addictive liability and constipation.
Related Concept Videos
Opioid Receptors: Overview
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
The Delta-to-Delta Circuit
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Adrenergic Antagonists: ɑ and β-Receptor Blockers

